Abstract
To the Editor: Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia.1 Frontal fibrosing alopecia (FFA) is considered a clinical variant of LPP.2 Limited evidence supports the therapeutic potential of tofacitinib, a Janus kinase (JAK)-1/3 inhibitor, for the treatment of recalcitrant LPP.3 The aim of our study was to evaluate the efficacy of baricitinib, a JAK-1/2 inhibitor, for the treatment of LPP.4
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
